Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing ...

Sanofi (SNY) is in discussions with the U.S. private equity firm Clayton Dubilier & Rice to sell a 50% stake in Opella.

Opella, Sanofi’s consumer healthcare business unit, generated sales of 1.3 billion euros, up 8%. Guidance: Earlier this week, Sanofi updated its 2024 business EPS guidance to at least a low ...

Advt The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi's consumer ...

Sanofi would maintain a 48% stake in Opella. Jones Day is advising Sanofi on the capital markets aspects of the separation of Opella and on real estate matters and vendor due diligence for the ...

Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic ...

The sale of a controlling 50-percent stake in Opella to CD&R values the maker of France's leading painkiller, Doliprane, at 16 billion euros ($17.4 billion), Sanofi said. "Sanofi and CD&R announce ...